Company / Cash & Equivalents
Benitec Biopharma Inc. Cash & Equivalents History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.8M
FY2021
5-year range
$9.8M / $15.7M
FY2020-FY2021
Trend
-37.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$10M in FY2021.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, cash & equivalents decreased 37.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.32 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $9.8M | -37.6% |
| FY2020 | $15.7M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026